Comparative Pharmacology
Head-to-head clinical analysis: VYVGART versus VYVGART HYTRULO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VYVGART versus VYVGART HYTRULO.
VYVGART vs VYVGART HYTRULO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neonatal Fc receptor (FcRn) antagonist; reduces IgG recycling, lowering pathogenic IgG autoantibody levels.
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) is a combination of efgartigimod alfa, a neonatal Fc receptor (FcRn) blocker, and hyaluronidase, an endoglycosidase that enhances subcutaneous fluid dispersion. Efgartigimod alfa binds to FcRn, reducing recycling of IgG and lowering plasma IgG levels, including pathogenic autoantibodies.
10 mg/kg intravenously over 1 hour, once weekly for 4 weeks (4 doses total), then 10 mg/kg intravenously over 1 hour every 2 weeks starting at week 5.
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) subcutaneous injection: For adult patients with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive, the recommended dosage is 1,008 mg efgartigimod alfa and 12,000 units hyaluronidase administered subcutaneously once weekly for 4 weeks. Subsequent cycles may be initiated based on clinical response, with at least one week between cycles; the safety and efficacy of initiating subsequent cycles more frequently than every 6 weeks have not been established.
None Documented
None Documented
Terminal half-life is approximately 80-120 hours (mean ~4 days). This supports a dosing interval of every 2 weeks after the initial weekly loading phase.
The terminal elimination half-life of efgartigimod alfa is approximately 14 days (range 12-18 days) following subcutaneous administration. This supports a dosing interval of once weekly for the initial cycle and every 2-4 weeks for maintenance.
Efgartigimod alfa is catabolized by general protein degradation pathways; no renal or biliary excretion of intact drug. Less than 1% of the dose is excreted unchanged in urine.
Efgartigimod alfa, the active component, is a human IgG1 antibody fragment; it is expected to be degraded into small peptides and amino acids via general protein catabolism. No specific renal or biliary excretion studies are available; as an antibody fragment, it is not excreted renally intact. Hyaluronidase (recombinant human) is locally degraded and does not contribute to systemic excretion.
Category C
Category C
FcRn Antagonist
FcRn Antagonist